1. Byrne P, Cullinan J, Smith A, Smith SM. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. BMJ Open. 2019;9(4):e023085. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500096/#R1
2. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41(1):111-188. https://doi.org/10.1093/eurheartj/ehz455
3. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
4. Kim MK, Han K, Joung HN, et al. Cholesterol levels and development of cardiovascular disease in Koreans with type 2 diabetes mellitus and without pre-existing cardiovascular disease. Cardiovasc Diabetol. 2019;18(1):139. https://doi.org/10.1186/s12933-019-0943-9
5. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Panduan Tata Laksana Dislipidemia 2017. http://www.inaheart.org/upload/image/lipid.pdf
6. Gidding SS, Allen NB. Cholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong Problem. J Am Heart Assoc. 2019 Jun 4;8(11):e012924.
7. Hadjiphilippou S, Ray KK. Cholesterol-Lowering Agents. Circ Res. 2019 Feb;124(3):354-363. doi:10.1161/CIRCRESAHA.118.313245
8. Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81. doi: 10.1161/ATV.0000000000000073
9. Chou R, Dana T, Blazina I, et al. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008–2024. https://jamanetwork.com/journals/jama/fullarticle/2584057
10. Li M, Wang X, Li X, et al. Statins for the Primary Prevention of Coronary Heart Disease. Biomed Res Int. 2019;2019:4870350. doi:10.1155/2019/4870350
11. Byrne P, Cullinan J, Smith A, Smith SM. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. BMJ Open. 2019;9(4):e023085. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500096/#R9
12. Taylor BA, Thompson PD. Statin-Associated Muscle Disease: Advances in Diagnosis and Management. Neurotherapeutics. 2018;15(4):1006-1017. doi:10.1007/s13311-018-0670-z
13. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596–e646.
14. Tong ST, Sabo RT, Hochheimer CJ, Brooks EM, Jiang V, Huffstetler AN, Lail Kashiri P, Krist AH. Uptake of Statin Guidelines to Prevent and Treat Cardiovascular Disease. J Am Board Fam Med. 2021 Jan-Feb;34(1):113-122. doi: 10.3122/jabfm.2021.01.200292. PMID: 33452089; PMCID: PMC7847084.
15. Kim JY, Choi J, Kim SG, Kim NH. Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study. Cardiovasc Diabetol. 2022 Feb 22;21(1):28. doi: 10.1186/s12933-022-01466-z. PMID: 35193571; PMCID: PMC8861991.
16. US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults, US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(8):746-753. doi:10.1001/jama.2022.13044
Facebook 
Masuk dengan Email
